# Cipla Ltd (CIPLA)
> Exchange: NSE | Sector: Pharma | ISIN: INE059A01026

## Price
Current Price: ₹1401.9
Day Change: +0.17%
52W High: ₹1672.2
52W Low: ₹1283
Market Cap: ₹1,15,638 Cr

## Valuation
P/E: 25.47
P/B: 3.51
EPS: ₹56.2
Book Value: ₹407.53
Dividend Yield: 0.9%

## Returns
1Y Return: -5.78%

## Profitability
ROE: 11.74%
ROCE: 23.95%
Debt/Equity: 0.02
Revenue Growth: -3.8%
Profit Growth: -54.6%
EBITDA Margin: 21.38%
Operating Margin: 9.5%

## About
Cipla is a leading Indian company in the Pharmaceuticals space, listed on the NSE. The company is a key player in the Pharma — Formulations segment with a strong market position and diversified operations.
Sector: Pharma
Industry: Drug Manufacturers - Specialty & Generic
Sub Industry: Pharma — Formulations

## Business Model
Overview: Cipla Ltd makes money through Core Business, Other Segments, Exports in Pharma — Formulations. Revenue quality depends on demand growth, margin discipline, balance-sheet strength, and the company's ability to defend its position within Pharma.
Source: Derived from stock data
Revenue Streams:
- Core Business
- Other Segments
- Exports
Operating Model:
- Develops, manufactures, distributes, or services healthcare products across regulated channels.
- Approvals, product mix, compliance quality, and R&D productivity shape growth.
Business Segments:
- Core Business: 63% of tracked revenue, equal to ₹21,934 Cr. | 63% | ₹21,934 Cr
- Other Segments: 31% of tracked revenue, equal to ₹10,793 Cr. | 31% | ₹10,793 Cr
- Exports: 6% of tracked revenue, equal to ₹2,089 Cr. | 6% | ₹2,089 Cr
Recent Context:
- Announcement: Announcement under Regulation 30 (LODR)-Newspaper Publication
- Concall Transcript: Announcement under Regulation 30 (LODR)-Earnings Call Transcript
- BSE Filing: Announcement under Regulation 30 (LODR)-Newspaper Publication

## Access
Current tier: anonymous
More history: Register free to see 8 more years.

## Data Freshness
Quote Updated: 2026-05-21T20:00:01.517Z
Price History Updated: 2026-05-17T21:29:36.898Z
Latest Price History Date: 2026-05-17
Technicals Updated: 2026-05-17T21:29:36.898Z
Quant Updated: 2026-05-17T21:29:36.898Z
Sentiment Updated: 2026-05-17T21:29:36.898Z
Financials Status: current
Financials Updated: 2026-05-18T02:34:19.186Z
Financials Last Attempt: 2026-05-18T02:34:19.186Z
Financials Provider Tried: yahoo
Latest P&L Period: FY25
Latest Balance Sheet Period: FY25
Latest Cash Flow Period: FY25

## P&L (Mar 2016)
Revenue: ₹11345 Cr
Operating Profit: ₹2163 Cr (OPM 19%)
Net Profit: ₹1229 Cr
Tax: ₹1654 Cr

## Annual P&L History
Mar 2016: Rev ₹11345Cr | PAT ₹1229Cr | OPM 19%
Mar 2017: Rev ₹13790Cr | PAT ₹1383Cr | OPM 18%
Mar 2018: Rev ₹14394Cr | PAT ₹1035Cr | OPM 17%

## Balance Sheet (Mar 2016)
Total Assets: ₹15670 Cr
Total Liabilities: ₹15670 Cr
Borrowings: ₹1703 Cr
Cash: ₹undefined Cr

## Shareholding
undefined: undefined%
undefined: undefined%
undefined: undefined%
undefined: undefined%
undefined: undefined%
undefined: undefined%
undefined: undefined%
undefined: undefined%
undefined: undefined%
undefined: undefined%
undefined: undefined%

## Board
- Achin  Gupta, MD, Global CEO & Additional Director
- Pradeep  Bhadauria, President & Global Chief Scientific Officer
- Ashish  Adukia, Global Chief Financial Officer
- Dinesh Ramniranjan Jain, Senior VP & Head of Corporate Finance
- Sneha  Hiranandani B Com, Chief Information Officer

## Highlights
- Strong revenue growth of 16% CAGR over 5 years
- ROE of 15.0% indicates efficient capital allocation

## Concerns
- Debt-to-equity ratio needs monitoring amid expansion plans
- Promoter holding has seen slight decline in recent quarters

---
Source: rupiya.io/stocks/cipla
Disclaimer: For research and education only. Not investment advice.